Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-cancer medicine composition containing antineoplastic antibiotics

An anti-cancer drug and composition technology, which can be applied in drug combinations, anti-tumor drugs, and medical preparations containing active ingredients, etc., and can solve problems such as difficulty in forming effective drug concentrations.

Inactive Publication Date: 2005-07-06
DASEN BIOLOGICAL PHARMA CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the excessive expansion and hyperplasia of solid tumors, the interstitial pressure, tissue elastic pressure, fluid pressure and interstitial viscosity are all higher than those of the surrounding normal tissues. Therefore, it is difficult for conventional chemotherapy to form an effective drug concentration in the tumor (see Kong Qingzhong "Intratumoral placement of cisplatin plus systemic carmustine in the treatment of rat brain tumors" "Journal of Surgical Oncology" 69 pages 76-82 (1998) (Kong Q et al., J Surg Oncol.1998 Oct; 69( 2): 76-82), simply increasing the dosage is limited by systemic reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Put 90 mg of polylactic acid (PLA) with a molecular weight of 20,000 into a container, add 100 ml of dichloromethane to dissolve and mix well, add 10 mg of anti-cancer active ingredient (orrubicin), shake again, and vacuum dry to remove organic solvents. The dried solid composition is immediately shaped, and after packaging, it is ray sterilized to obtain an anticancer pharmaceutical composition containing 10% ororubicin.

Embodiment 2

[0063] As described in Example 1, the difference is that the anti-cancer active ingredients contained are:

[0064] (a) 1%-50% 7-O-Methyl Noga-4'-Epirubicin, Arubicin, Aclarithromycin-B, Amrubicin, 4'-(horseradish biphenyl Amino phenacylamine), 4-demethoxydaunorubicin, ditorubicin, epirubicin, esorubicin, carrubicin, idarubicin, rhodorubicin , Rhorubicin, metopixin, nemorubicin, doxorubicin, pirarubicin, pirarubicin, orrubicin, 2-[4-(7-chloro-2-quinone Oxalinyloxyphenoxy]-propionic acid, zorubicin or N-(2-chloroethane)-N-nitrosouridodaunorubicin; or

[0065] (b) 1%-50% losanantrone, losoxantrone, piroxantrone, tiloxantrone, carcinomycin, pelyomycin, pelyomycin sulfate, antibiotic 1588, exodin, Adazolam hydrochloride, adazolam, cladamycin, acetylcladamycin, azithromycin, sniperformin, triiron adriamycin, diethoxyacetyl adriamycin, cyclomycin, Carcinostatin, carcinophilin, oncinotropin, oncobacterin, carcinogen, diazomycin, bacterin, bacteromycin, alanin or alanin; or

[0066] (c) 1...

Embodiment 3

[0070] Put 90mg of polyglycolic acid and glycolic acid copolymer (PLGA) with a molecular weight of 20,000 into the container, add 100ml of dichloromethane to dissolve and mix well, add 10mg of anticancer active ingredient (idarubicin), and shake again The organic solvent was removed by vacuum drying. The dried solid composition is immediately shaped, and after packaging, it is ray sterilized to obtain an anticancer pharmaceutical composition containing 10% idarubicin. The anti-cancer drug composition is kept under the skin of the mice, and the drug content is measured regularly, and the cumulative release percentage (%) is calculated according to the remaining drug amount. It was found that 80-95% of the drug was released uniformly within 30 days. The above are all percentages by weight.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An anticancer pharmaceutical composition composed of pharmaceutic adjuvant and enwrapped in anti-tumor drug is provided. Wherein the anti-tumor drug is tumor resistant antibiotic, the pharmaceutic adjuvant is mainly biological compatible, degradable and absorbable macromolecule polymer. The anticancer drug can be sustained released to local tumor region in the degradation and absorption process, as a result, it can both decrease whole body toxic reaction considerably and maintain tumor local effective drug level.

Description

(1) Technical field [0001] The invention relates to an anticancer pharmaceutical composition, which belongs to the technical field of medicines. (2) Background technology [0002] The treatment of cancer mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutics used, anti-tumor antibiotics have obvious effects and have been widely used in a variety of malignant tumors. However, the blood vessels, connective tissue, matrix proteins, fibronectin, and collagen in the tumor stroma not only provide scaffolds and essential nutrients for the growth of tumor cells, but also affect the chemotherapeutic drugs around the tumor and tumor tissues. Internal penetration and diffusion (see Netti et al. "The effect of extracellular matrix conditions on drug delivery in solid tumors", Cancer Research, Issue 60, pages 2497-503 (2000) (Netti PA, Cancer Res. 2000, 60 (9): 2497-503). Due to the excessive swelling and hyperplasia of solid tumors, the interstitial press...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61P35/00
Inventor 孔庆忠
Owner DASEN BIOLOGICAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com